JC03 Rec'd PCT/PTO 04 APR 200

PTO/SB/21 (09-0
Approved for use through 07/31/2006. OMB 0651-003

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Application Number

APR S	TO SEE		U.S	Detect and To	madamaele	Office: I	PTO/SB/21 (09-04) through 07/31/2006. OMB 0651-0031 J.S. DEPARTMENT OF COMMERCE		
Mader the Pa	per Work Reduction Act of 1995	, no persons	are required to respond to a c Application Number	10/520,016	ormation u	unless it	displays a valid OMB control number.		
TR	ANSMITTAL	-	Filing Date	12/29/2004					
	FORM	-	First Named Inventor	Okada, Hid					
	I OINII	-	Art Unit	Okada, Tilo	accilina .				
		-	Examiner Name				· · · · · · · · · · · · · · · · · · ·		
(to be used for	(to be used for all correspondence after initial filling)  Attorney Docket Number								
Total Number of Pages in This Submission 36 Attorney Docket Number 3348/2									
ENCLOSURES (Check all that apply)									
	smittal Form		rawing(s)			Appea	Allowance Communication to TC  Il Communication to Board		
	ee Attached		censing-related Papers			• • •	eals and Interferences		
Amendme	ent/Reply		etition etition to Convert to a				Il Communication to TC Il Notice, Brief, Reply Brief)		
│	fter Final	Pr	rovisional Application			Propri	etary Information		
Af	fidavits/declaration(s)		ower of Attorney, Revocati hange of Correspondence			Status	Letter		
l — 3	of Time Request	Те	erminal Disclaimer				Enclosure(s) (please Identify		
Extension of time request			equest for Refund		Copy of International Search Report		rnational Search Report; Return		
Information	on Disclosure Statement	CI	D, Number of CD(s)			•	·		
			Landscape Table on C	CD					
Certified (	Copy of Priority	Remarks							
Documen	` '		arge Deposit Account No.	01-0265 if th	here are	any fee	s due in connection with this		
	Missing Parts/ te Application	matter.							
R∈	eply to Missing Parts nder 37 CFR 1.52 or 1.53								
"	ide: 37 Of IC 1.32 of 1.33								
	OLONA	TUDE DE	- A DDI IO ANT	200	ND 400	- \ 1 -			
Firm Name	SIGNA	AL I	APPLICANT, ATTO	JRNET, U	JR AGE	=N I			
i iiii wanie	ADAMS EVANS P.A.	MI	6//0//	1/2	~				
Signature	Signature ( ) Walk ( ) Walk ( )								
Printed name	W. Thad Adams, III	10 10		<u>,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,</u>					
Date	3/30/2005			Reg. No.	29,037				
CERTIFICATE OF TRANSMISSION/MAILING									
sufficient postage	I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:								
Signature	Signature Q. Dominary								
Typed or printed a		1 1	0			Date	3/30/2005		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Col	Complete if Known			
	Application Number	10/520,016			
INFORMATION DISCLOSURE	Filing Date	12/29/2004			
	First Named Inventor	Okada, Hidechika			
STATEMENT BY APPLICANT	Art Unit				
(Use as many sheets as necessary)	Examiner Name				
Sheet 1 of 2	Attorney Docket Number	3348/2			

			U. S. PATENT D		
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
		Number-Kind Code <sup>2 (# known)</sup>	-		1.92.007.4500.
		US-			
		US- ,			
		US-		• •	
		US-			
		US-		,	
		US-		<del></del>	
	1	1	1		1

		FORE	IGN PATENT DOCU			
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	
	1	WO97/22361	06-26-1997	Otsuka		
				-		L
						Ĺ
						L
				1		Γ

Examiner	Date	
Signature	Considered	
-		3

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Juder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/520,016	
INF	ORMATION	DIS	CLOSURE	Filing Date	12/29/2004	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Okada, Hidechika	
(Use as many sheets as necessary)				Art Unit		
				Examiner Name		
Sheet	2 .	of	2	Attorney Docket Number	3348/2	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	2	OKADA et al., "Tosa Kogen GM2 ni Taisuru Hito-gata IgM Kotai no Ko-HIV Kassei", Nagoya Shiritsu Daigaku Igakukai Zasshi, 1999, Vol. 50, No. 1/2, pg. 9-13	
	3	XIAOSHAN et al., "The IgM antibody level against ganglioside GM2 correlates to the disease status of HIV-1-infected patients" Microbiology & Immunology 2000, Vol. 44, No. 5, pg. 405-410	
	4	OKADA et al., "Human IgM monoclonal antibody to ganglioside GM2 and complement suppress virus propagation in ex vivo cultures of lymphocytes from HIV-1 infected patients, 1999, Vol. 43, No. 7, 19.72	3-72
	5	ASAI et al., "HIV-1 Kansen Saibo ni Hanno suru IgM Kotai no Hotai Kasseikano to Amino-san Hairetsu tono Kanrensei", Hotai Symp.Nihon Seeitai Bogyo Gakkai Godo Gakujutsu Shukai Koenshu 2002, Vol. 3, Nos. 3–9, pg. 35	

Signature Considered	Examiner	Date	
	Signature		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.